Skin Cancer

Protective clothing can help prevent skin cancers by blocking the sun's ultraviolet rays.

A melanoma survivor shares her experience and ideas.

When melanoma metastacizes, the lymph node to which it has spread is typically removed. But what if micrometastases are found in other nearby lymph nodes? Should patients undergo a complete dissection, or removal, of all the nodes in the area?

A breast cancer survivor shares ways she copes with fear of recurrence while waiting for her latest mammogram results.

Significant strides have been made in the treatment of patients with immunotherapies and targeted therapies. However, determining which therapies are best for which patients and how to treat patients who don't respond or stop responding to these new therapies is still a challenge.

A breast cancer and melanoma survivor reflects on the emotions and experiences after surgeries, chemotherapy and radiation are completed.

For those with a history of non-melanoma skin cancer (NMSC), reducing their risk of recurrence can be as simple as taking the vitamin B3 pill nicotinamide.

A breast cancer and melanoma survivor shares her thoughts on time as well as her biopsy results.

In a combined decision, members of the FDA's Oncologic Drugs Advisory Committee and Cellular, Tissue and Gene Therapies Advisory Committee (CTGTAC) voted 22-1 to recommend approval of T-VEC.

The FDA has assigned a priority review designation to Opdivo (nivolumab) as a treatment for previously untreated patients with unresectable or metastatic melanoma.

A breast cancer and melanoma survivor shares her perspective on living with "wait and watch."

Pembrolizumab (Keytruda) elicited significantly better outcomes compared with ipilimumab (Yervoy) in a randomized phase 3 trial of patients with advanced melanoma.

Frontline immunotherapy with Opdivo (nivolumab) plus Yervoy (ipilimumab) delayed disease progression by 60 percent compared with Yervoy alone in patients with advanced melanoma.

Kevin B. Kim, of the California Pacific Medical Center, explains how patients with melanoma who are in remission can get back into a normal, daily routine while still taking precautions.

At age 22, Megan Miller was diagnosed with basal cell carcinoma, a common form of skin cancer that can be easily treated. But a year later, she was diagnosed with melanoma.

In 1995, Sam Donaldson, ABC news veteran, found a lump that ultimately led to a diagnosis of melanoma.

The development of agents targeting the PD-1 immune checkpoint in the treatment of patients with advanced melanoma is progressing rapidly.

A trial comparing frontline Keytruda (pembrolizumab) with Yervoy (ipilimumab) for the treatment of advanced melanoma has met its progression-free survival and overall survival endpoints.

The FDA has granted a priority review to the MEK inhibitor cobimetinib for use in combination with the BRAF inhibitor Zelboraf to treat patients with BRAF V600–positive advanced melanoma.

Richard Joseph, assistant professor of medical oncology at Mayo Clinic in Jacksonville, Florida, explains how treatment outcomes for metastatic melanoma have grown in the past few years.

Omid Hamid, chief of clinical research and immunotherapy at The Angeles Clinic and Research Institute, explains how he helps ease his patients' fears after a diagnosis of metastatic melanoma.

Melanoma rates are on the rise, and is the most common form of cancer for young adults aged 25 to 29 years old.

Enormous medical gains have been made against melanoma over the past four years, and more are waiting in the wings.

At least 10 vaccine candidates have entered advanced testing phases on the strength of impressive early stage results.

Melanoma specialist, Suzanne L. Topalian discusses how new approved drugs and those in the pipeline for advanced melanoma are making an impact for patient.

In the past four months, the PD-1 inhibitors Opdivo (nivolumab) and Keytruda (pembrolizumab) have been approved for the treatment of advanced melanoma. Jeffery S. Weber, a senior member at Moffitt Cancer Center in Tampa, Fla., provides insight on what this means for treating patients.

The Food and Drug Administration's calendar for making decisions on new cancer drugs and indications is taking shape for 2015, and the clock is ticking on at least 13 applications for novel agents and new therapeutic settings for existing drugs.

The PD-1 inhibitor Opdivo (nivolumab) was granted accelerated approval for patients with unresectable or metastatic melanoma following treatment with Yervoy (ipilimumab) or a BRAF inhibitor.

The annual meeting of the European Society for Medical Oncology (ESMO) was held in September to discuss the latest data on critical issues in cancer treatment, diagnostics, prevention, supportive care and more.

Several studies announcing the latest research in different cancers, including prostate, breast and lung cancers, were presented at the 2014 European Society of Medical Oncology's annual meeting in Madrid, Spain.